Brief: Aileron Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Business Highlights
28/03/2022 22:39
March 28 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS
* AILERON THERAPEUTICS - EXPECTS, EXISTING CASH, CASH
EQUIVALENTS
AND INVESTMENTS WILL FUND OPERATIONS INTO Q4 OF 2023
* AILERON THERAPEUTICS INC - QTRLY NET LOSS PER SHARE $0.08
Source text for Eikon: ID:nGNX70zCnp
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering